Disclosed is the use of a steroid sparing agent for the preparation of a medicament which reduces and/or eliminates a need for steroid treatment in a subject with multiple sclerosis, wherein the medicament comprises a steroid sparing effective amount of natalizumab and wherein the subject is on steroids.